ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1825

Exploring the Health and Cannabis Use Among Young and Middle-Aged Adults with Rheumatologic Conditions in Alberta, Canada
Abstract Number: 2424

Exploring the Limit of Image Resolution for Human Expert Classification of Vascular Ultrasound Images in Giant Cell Arteritis and Healthy Subjects: The GCA-US-AI Project
Abstract Number: 1719

Exploring the Link Between Osteitis and Bone Microstructure Changes in Rheumatoid Arthritis: Role of JAK-STAT Signaling Pathway
Abstract Number: 1791

Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622
Abstract Number: 0270

Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety
Abstract Number: 2065

Exploring the Power of Ultrasound in Rheumatology: Insights from Young Rheumatologists in Mexico
Abstract Number: 1069

Exploring the Risk of Demyelination Associated with TNF Alpha Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS)
Abstract Number: 1643

Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis
Abstract Number: 1566

Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica
Abstract Number: 0083

Expression of mRNA Vaccine Antigen in Hematopoietic Cells Is Necessary for Induction of Optimal Vaccine-Specific CD4+ T Cell Responses
Abstract Number: 0791

Expression of TL1A, Inflammatory, and Fibrotic Pathways in Patients with Diffuse Systemic Sclerosis
Abstract Number: 1988

Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis
Abstract Number: 0140

Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database
Abstract Number: 1194

Extent of Subregional Involvement of Subchondral Bone Marrow Lesions in Incident Knee OA Is Associated with Weight-Bearing Knee Pain
Abstract Number: 1223

Extracorporeal Life Support for Childhood-Onset Systemic Lupus Erythematosus: An ELSO Registry Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].